Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Among authors: garassino mc. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Pietrantonio F, Garassino MC, Torri V, de Braud F. Pietrantonio F, et al. Among authors: garassino mc. Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8. Ann Oncol. 2012. PMID: 22875835 Free article. Clinical Trial. No abstract available.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC. Agustoni F, et al. Among authors: garassino mc. Cancer Treat Rev. 2014 Feb;40(1):197-203. doi: 10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10. Cancer Treat Rev. 2014. PMID: 23850197 Free article. Review.
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists. Garassino MC, et al. Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22. Lancet Oncol. 2013. PMID: 23883922 Clinical Trial.
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Haspinger ER, et al. Among authors: garassino mc. J Clin Oncol. 2014 Mar 10;32(8):859-63. doi: 10.1200/JCO.2013.52.8794. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493720 Free article. No abstract available.
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Haspinger ER, Agustoni F, Torri V, Gelsomino F, Platania M, Zilembo N, Gallucci R, Garassino MC, Cinquini M. Haspinger ER, et al. Among authors: garassino mc. Crit Rev Oncol Hematol. 2015 May;94(2):213-27. doi: 10.1016/j.critrevonc.2014.11.005. Epub 2014 Nov 22. Crit Rev Oncol Hematol. 2015. PMID: 25523487 Review.
A lesson from vorinostat in pleural mesothelioma.
Garassino MC, Marsoni S. Garassino MC, et al. Lancet Oncol. 2015 Apr;16(4):359-60. doi: 10.1016/S1470-2045(15)70084-7. Epub 2015 Mar 20. Lancet Oncol. 2015. PMID: 25800895 No abstract available.
EGFR mutations and EGFR tyrosine kinase inhibitors.
Torri V, Broggini M, Garassino MC. Torri V, et al. Among authors: garassino mc. Lancet Oncol. 2015 Jul;16(7):746-8. doi: 10.1016/S1470-2045(15)00028-5. Epub 2015 Jun 4. Lancet Oncol. 2015. PMID: 26051233 No abstract available.
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC; TAILOR trialists. Rulli E, et al. Among authors: garassino mc. Ann Oncol. 2015 Oct;26(10):2079-84. doi: 10.1093/annonc/mdv318. Epub 2015 Jul 24. Ann Oncol. 2015. PMID: 26209642 Free article. Clinical Trial.
Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Lo Russo G, et al. Among authors: garassino mc. Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Tumour Biol. 2016. PMID: 26943800 Review.
251 results